Key Takeaways
- Challenging H1 ahead, H2 recovery expected: Management called H1 FY24 "challenging" but expects a significantly better H2 as channel inventory normalizes from September/October onwards, with full-year growth still anticipated.
- Margins clawing back toward FY22 levels: Q4 FY23 operating margins expanded sequentially to ~17%, and the company expects FY24 EBITDA to exceed FY23, with H2 FY24 margins far better than H1 and an exit run rate moving toward FY22 levels.
- Animal Health facility is the next growth leg: The new multipurpose US FDA-standard plant commercializes end of Q2 FY24, with validation-batch revenue flowing over the next 14–18 months and full commercial production driving higher revenue and profit from FY25.
- China Plus One inquiries have surged irreversibly: Management sees the shift as a structural, long-term decision by customers, with projects already signed and launches planned this year and next across both pharma and crop protection.
- What to watch next quarter: Whether the Panoli crop protection multipurpose plant and Animal Health facility commission on schedule, the pace of channel inventory drawdown, and any early signs that H2 demand recovery is materializing.
Margin Recovery Path
- Sequential improvement delivered: Q4 FY23 margins reached ~17%, close to historical levels, after step-wise improvement through the year despite limited top-line growth, driven by cost management, supply chain optimization, procurement streamlining, and product mix improvement.
- Product mix shift helped pharma: Even with 11% pharma volume de-growth for FY23, the company sold more high-margin products, partially insulating margins from volume pressure.
- Raw material tailwind emerging: Softening raw material prices are expected to benefit margins starting from end of Q1 FY24, with a lag effect of one to three quarters on CDMO contracts where pass-through clauses exist.
- Staff cost overhang is temporary: Staff costs rose because new employees were onboarded well in advance for new plants, with induction and training periods of a few months to a couple of quarters before commissioning; this normalizes once plants reach steady state by next year.
- New projects carry structurally better margins: Management stated new projects have a better margin profile compared to historical business, which supports the margin expansion thesis as these assets ramp.
Sameer Hiremath: "From H2 FY24 onwards, we'll start moving towards the FY22 margins exit run rate. And after that, from FY25 onwards, we expect this sequential growth to come back. I think there's a little bit of pause for 1.5 years because of market conditions and external environment, but the medium to long-term perspective, we are still at confident goal."
Animal Health: The Next Growth Engine
- Facility on track: The new multipurpose Animal Health facility in Panoli, built to US FDA standards, is on schedule to be commercialized at the end of Q2 FY24.
- Revenue ramp has two phases: Validation batches will be supplied over the next 14–18 months (till end of FY25), generating revenue and profits during that period; full commercial production begins thereafter, generating higher revenues and higher profits.
- Peak utilization timeline: Reaching peak optimization will take 2.5 to 3 years from start, with revenues generated throughout the ramp-up period, albeit smaller initially.
- Competitive positioning: Hikal claims to be one of the few with a fully compliant cGMP facility for animal health, giving it a cutting edge; in the CDMO space for animal health, management sees no like-to-like competitor in India, with only a few large CDMO players in Europe and China.
- Fungible asset, not client-dedicated: The facility is a fungible multipurpose asset that will serve multiple global clients, with products spanning proprietary and proprietary generics, some off-patent and some on-patent, developed from scratch.
- Separate organization built: A dedicated Animal Health organization with sales and marketing, operations, R&D, and procurement has been established, headed by Anish Swadi, and currently sits within the pharmaceutical division.
Anish Swadi: "We'll commercialize the plant in the end of Q2... We'll supply validation batches of all the products that we have over the next 14 months to 18 months, which is basically till the end of next financial year. And then we'll start full commercial production. So we will generate revenue and profits in the next 14 months to 18 months, and then the commercial quantities will start, whereby we will generate higher revenues and higher profits."
Pharma: Pricing Stabilization & Portfolio Shift
- Price erosion easing: The rate of price erosion in pharma is lower than what was experienced in 2022, with management stating the worst of erosion is likely behind, supported by improved raw material and logistics costs.
- Generic API competition is structural and intense: Any DMF filed sees replication of at least 10–15 DMFs of the same product, with customers negotiating multiple API sources against each other; competition is primarily from India-based companies, not China, on Hikal's product portfolio.
- Defense is early launch and cost leadership: Management's stated strategy is to be early to launch and stay ahead on the cost curve, because without a competitive advantage, the business falls into the trap of price reduction.
- Legacy dependence declining: The percentage of reliance on the legacy pharma portfolio is coming down year-on-year, though the business on these products will still grow as the end market grows and Hikal retains market share.
- New launches pipeline: The company targets launching 3–4 products by end of FY24 from a pipeline of 8–10 products under development, with a cadence of three to four new launches every year.
- CDMO normalization expected H2 FY24: After a period of softness, the CDMO industry is anticipated to normalize in H2 FY24, with two opportunities in Phase 3 clinical trials likely to become commercial in coming years.
Manoj Mehrotra: "Any DMF, which we file, there will be a replication of at least 10 to 15 DMFs of the same product. So the only way to stay ahead of the competition, it really be a little early for launch, number one. And number two, always be ahead in the cost curve... And if you really don't have any competitive advantage, you tend to fall in the trap of price reduction."
Crop Protection: Near-Term Pain, CDMO Traction
- Own-product demand subdued: Demand for own products remained subdued in Q4 FY23 due to high channel inventory, a trend expected to continue during H1 FY24, with improvement expected from September/October onwards.
- CDMO inquiries picking up: The company is witnessing increased traction in inquiries in the CDMO segment, even as own-product demand lags.
- Q4 EBIT surge: Crop Protection EBIT grew 167% YoY to INR 31 crores in Q4 FY23, despite the subdued demand environment.
- Multipurpose plant adds flexibility: The Panoli multipurpose plant, nearing completion and in stabilization phase, will be fungible between own products and CDMO products, allowing the company to flex with demand conditions.
- Medium-term demand intact: End-user consumption continues to grow, supporting a positive medium-term outlook once channel inventory normalizes.
Capex Cycle Nearing Completion
- Two major projects commissioning soon: The Animal Health plant and the Crop Protection multipurpose plant, both in Panoli, will be commissioned by Q2 FY24, marking the end of the major capex cycle.
- No new major capex planned: Going forward, only maintenance capex and small debottlenecking capex are planned for this year, signaling a shift to harvesting the investments made.
- Pharma capex now contributing: Capex in Bangalore was just capitalized, and Panoli pharma capex was capitalized a year before; revenue has started coming in, with commercial sales happening in FY23 and FY24 after an initial year focused on validation.
- Panoli US FDA approval unlocks dual-site strategy: The Panoli API facility received US FDA approval with NAI status and Zero 483 observations, becoming Hikal's second US FDA-approved API site; this allows validation of products between two sites (Jigani and Panoli), supports CDMO strategy, and enables contingency planning for supply security, viewed very positively by customers.
China Plus One: Structural Tailwind
- Inquiries have surged: Management reported a tremendous increase in China Plus One inquiries over the last year, with many projects signed, many under development, and some to be launched this financial year and next.
- Irreversible shift: Customers are looking at this from a long-term perspective, not a short-term impact, and decisions have already been made at the senior-most levels; the move is happening in both pharma and crop protection, though pharma takes slightly more time due to the regulatory environment.
- Niche molecules insulated from short-term Chinese pricing pressure: The CDMO segment and niche molecules are not facing the same short-term pricing pressure from China as commodity products, because the decision is structural rather than price-driven.
Sameer Hiremath: "I think the decisions have already been made. And customers are not looking at just as a short-term impact. They are looking at it more from a long-term perspective... all is not going to move to India, but even if a fraction of what the China moves to India, is going to keep all the top Indian companies busy for several years to come."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Channel inventory normalization | Higher than normal inventory levels with customers expected to ease | Towards end of Q2 FY24 |
| Animal Health plant commercialization | Plant operational, validation batches supplied over next 14–18 months, then full commercial production | End of Q2 FY24 |
| Crop Protection multipurpose plant commissioning | Plant in stabilization phase, commissioning progressing as planned | Next few months (Q2 FY24) |
| API product launches | 3–4 products launched from pipeline of 8–10 under development | By end of FY24 |
| Full-year FY24 margins | Margins not contract to slightly expand vs FY23; FY24 EBITDA better than FY23 EBITDA | FY24 |
| H2 FY24 margin trajectory | H2 margins far better than H1; Q4 FY24 margins better than Q4 FY23 | H2 FY24 |
| Margin run-rate recovery | Start moving towards FY22 margins exit run rate | From H2 FY24 onwards |
| Sequential growth return | Sequential growth expected to come back once new capacities start kicking in | From FY25 onwards |
| Animal Health peak utilization | Reach peak optimization | 2.5 to 3 years from start |
| Capex | No new major capex; only maintenance and small debottlenecking | FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹545 cr, +8.5% YoY |
| Full-year revenue | ₹2,023 cr, +4% YoY |
| EBITDA (full year) | ₹257 cr, vs ₹341 cr in FY22 |
| Profit after tax | ₹36 cr (Q4), ₹78 cr (full year) |
| Pharma revenue | ₹309 cr, +0.3% YoY |
| Pharma EBIT margin | 11.7%, EBIT of ₹36 cr |
| Crop Protection revenue | ₹236 cr, +22% YoY |
| Crop Protection EBIT margin | 11.4%, EBIT of ₹31 cr, +167% YoY |
| Debt-to-equity ratio | 0.61x, vs 0.59x in FY22 |
| Dividend per share (FY23) | ₹1.20, 60% of face value |
| Pharma volume growth | +10% YoY |
| Crop Protection volume growth | -13% YoY |
| Pharma CDMO vs own products mix | ~50-50, varies quarter-to-quarter |
| R&D spend | ~4% of revenue, 3.5%–4% range |
| DMF filings (FY23) | 3 filed, plan for 3–4 annually |
| Capex (last 3 years) | ₹700 cr |
| Capex (FY24 estimate) | ₹200 cr |
| Animal Health commercial timeline | ~1 year 9 months from May 2023 to full commercial supplies |